AbbVie Inc. $ABBV Stock Sold by Letko Brosseau & Associates Inc.

Letko Brosseau & Associates Inc. lowered its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.0% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 264,679 shares of the company’s stock after selling 5,330 shares during the quarter. Letko Brosseau & Associates Inc.’s holdings in AbbVie were worth $69,237,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Burk Holdings LLC purchased a new position in shares of AbbVie in the second quarter worth about $30,000. Marquette Asset Management LLC lifted its holdings in shares of AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares during the period. IMG Wealth Management Inc. lifted its holdings in shares of AbbVie by 3,060.0% during the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after purchasing an additional 153 shares during the period. Principia Wealth Advisory LLC boosted its position in AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after buying an additional 44 shares during the last quarter. Finally, Tacita Capital Inc purchased a new stake in AbbVie in the second quarter valued at approximately $42,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ABBV shares. Canaccord Genuity Group increased their price target on shares of AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. BMO Capital Markets set a $315.00 price objective on shares of AbbVie in a research note on Wednesday, November 4th. UBS Group lifted their price objective on shares of AbbVie from $275.00 to $295.00 and gave the company a “neutral” rating in a research note on Monday, November 2nd. Cantor Fitzgerald increased their price objective on shares of AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a research note on Monday, November 2nd. Finally, Wells Fargo & Company raised their target price on shares of AbbVie from $300.00 to $340.00 and gave the stock an “overweight” rating in a report on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $297.46.

AbbVie Stock Down 0.1%

Shares of ABBV opened at $294.75 on Friday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $302.93. The company has a market capitalization of $521.01 billion, a price-to-earnings ratio of 50.73, a PEG ratio of 1.34 and a beta of 0.20. The stock’s 50-day moving average price is $274.82 and its 200-day moving average price is $240.55.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping the consensus estimate of $3.73 by $0.09. The firm had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. AbbVie’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $1.86 earnings per share. As a group, equities analysts anticipate that AbbVie Inc. will post 13.98 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be given a $1.82 dividend. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s payout ratio is currently 119.10%.

Key AbbVie News

Here’s some of the latest news about ABBV:

• Positive Sentiment: AbbVie recently raised its 2026 revenue guidance to about $67.8 billion and increased its dividend after reporting third-quarter revenue of $17.4 billion. These updates reinforce the company’s earnings and shareholder-return outlook. Can AbbVie Justify Its Valuation After Raised Guidance and Strong Results?
• Neutral Sentiment: A Crohn’s disease study update drew coverage describing its likely near-term stock impact as limited; it does not appear to materially change the immediate investment outlook. AbbVie Crohn’s Disease Study Update
• Negative Sentiment: Executive Vice President Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. Insider sales can weigh on sentiment, though the filing does not explain the reason for the transaction. SEC Form 4 filing

Insider Buying and Selling

In other news, EVP Jeffrey Stewart sold 40,619 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at $24,419,005.60. This trade represents a 32.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.06% of the company’s stock.

AbbVie Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.